SJEPD031372_D1.RNA-Seq
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 10.75
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -2.994842938
- umap2_2d
- 2.106256174
- umap1_3d
- -0.392634523
- umap2_3d
- 3.421395773
- umap3_3d
- -2.505539165
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.600
- E2F_TARGETS+0.590
- MITOTIC_SPINDLE+0.380
- MYC_TARGETS_V1+0.270
- PANCREAS_BETA_CELLS+0.200
- PROTEIN_SECRETION+0.150
- SPERMATOGENESIS+0.100
- HEDGEHOG_SIGNALING+0.060
- WNT_BETA_CATENIN_SIGNALING+0.060
- MTORC1_SIGNALING+0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- IL6_JAK_STAT3_SIGNALING-0.490
- MYOGENESIS-0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- TNFA_SIGNALING_VIA_NFKB-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- INTERFERON_GAMMA_RESPONSE-0.410
- XENOBIOTIC_METABOLISM-0.410
- COAGULATION-0.390
- P53_PATHWAY-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NKRYMHEP | medulloblastoma | — | 0.935 |
| 2 | SRR975565 | — | — | 0.930 |
| 3 | BS_3F5PR9GS | medulloblastoma | — | 0.924 |
| 4 | SJEPD031150_D1.RNA-Seq | EPN | EPN Tumor | 0.923 |
| 5 | BS_7XQRH69M | medulloblastoma | — | 0.916 |
| 6 | SRR13780268 | — | cohortSC | 0.916 |
| 7 | BS_45J79YTF | high-grade glioma | — | 0.915 |
| 8 | BS_FBJ5Q54N | Embryonal tumors | — | 0.914 |
| 9 | BS_M15PW2N0 | medulloblastoma | — | 0.914 |
| 10 | BS_A14Z8BBK | medulloblastoma | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.020 | Idelalisib | — uncovered |